

28 sto

Phospho-PI3 Kinase p85 (Tyr458)/p55 (Tyr199) Antibody



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: M	Sensitivity: Endogenous	MW (kDa): 60 and 85	Source/Isotype: Rabbit	UniProt ID: #P27986, #Q92569, #O00459	Entrez-Gene Id 5295, 8503, 529	
Product Usage Information		Application Western Blotting Immunoprecipitation	tern Blotting 1:1000				
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μ g/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.					
Specificity/Sensitivity		Phospho-PI3 Kinase p85 (Tyr458)/p55 (Tyr199) Antibody detects endogenous levels of p85/p55 only when phosphorylated at Tyr458/Tyr199.					
Species predic based on 100% homology	ted to react 6 sequence	Human					
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr458 of mouse p85. Antibodies are purified by protein A and peptide affinity chromatography.					
Background		Phosphoinositide 3-kinase (PI3K) catalyzes the production of phosphatidylinositol-3,4,5-triphosphate by phosphorylating phosphatidylinositol (PI), phosphatidylinositol-4-phosphate (PIP), and phosphatidylinositol-4,5-bisphosphate (PIP ₂). Growth factors and hormones trigger this phosphorylation event, which in turn coordinates cell growth, cell cycle entry, cell migration, and cell survival (1). PTEN reverses this process, and research studies have shown that the PI3K signaling pathway is constitutively activated in human cancers that have loss of function of PTEN (2). PI3Ks are composed of a catalytic subunit (p110) and a regulatory subunit. Various isoforms of the catalytic subunit (p110 α , p110 β , p110 γ , and p110 δ) have been isolated, and the regulatory subunits that associate with p110 α , p110 β , and p110 δ are p85 α and p85 β (3). In contrast, p110 γ associates with a p101 regulatory subunit that is unrelated to p85. Furthermore, p110 γ is activated by $\beta\gamma$ subunits of heterotrimeric G proteins (4). Protein extracts from 3T3-Src cells were profiled by PhosphoScan® to identify phosphotyrosine peptides. Tyr458 of PI3K p85 and Tyr199 of PI3K p55 were among 180 phosphopeptides and 185 phosphotyrosine sites identified (5).					
Background References		3. Neri, L.M. et al. (2002 4. Stoyanov, B. et al. (19	sons, R. (2001) <i>Exp</i> 2) <i>Biochim Biophys</i> 995) <i>Science</i> 269, 6	s, R. (2001) <i>Exp Cell Res</i> 264, 29-41. <i>liochim Biophys Acta</i> 1584, 73-80.			
Species Reacti	vity	Species reactivity is de	termined by testin	g in at least one appro	ved application (e.g., w	restern blot).	
Western Plet Buffer		IMPORTANT: For western blots, insubate membrane with diluted primary antibody in ENA WAY PSA 1V					

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4° C with gentle shaking, overnight.

Applications Key

W: Western Blotting IP: Immunoprecipitation

Cross-Reactivity Key

M: Mouse

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.